Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2599503 | 0.98 | DRD2 (0.48) | DRD2HTR2ADRD3SSTR4HTR1A | |
| SCHEMBL27915442 | 0.86 | DRD2 (0.48) | DRD2HTR2ADRD3SSTR4HTR1A | |
| SCHEMBL28106582 | 0.82 | DRD2 (0.43) | DRD2HTR2ADRD3SSTR4HTR1A | |
| SCHEMBL2321092 | 0.79 | SLC6A4 (0.54) | DRD2SLC6A2SLC6A4SLC6A3MTNR1A | |
| SCHEMBL9703831 | 0.77 | DRD2 (0.46) | DRD2HTR2ADRD3HTR1A | |
| SCHEMBL10746746 | 0.77 | HTR2C (0.47) | DRD2HTR2ADRD3HTR1ASLC6A2 | |
| SCHEMBL1639063 | 0.77 | DRD2 (0.46) | DRD2HTR2ADRD3HTR1ASLC6A2 | |
| SCHEMBL30752424 | 0.77 | DRD2 (0.46) | DRD2HTR2ADRD3HTR1ASLC6A2 | |
| SCHEMBL2787499 | 0.77 | HTR1A (0.47) | DRD2HTR2ADRD3HTR1AKCNH2 | |
| SCHEMBL7963983 | 0.77 | DRD2 (0.46) | DRD2HTR2ADRD3HTR1ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571858-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | Research Triangle Institute (US) | 2013-03-27 | — | — | EP | claimed |
| WO-2011146850-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | RESEARCH TRIANGLE INSTITUTE (US) | 2011-11-24 | — | — | WO | claimed |
| US-9617229-B2 | Phenylmorpholines and analogues thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2017-04-11 | — | — | US | disclosed |
| US-20130203752-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | NIH-DEITR | 2013-08-08 | — | — | US | disclosed |
| EP-2571858-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | Research Triangle Institute (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011146850-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | RESEARCH TRIANGLE INSTITUTE (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203752-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | PNMT, OPRL1, OPRM1 | DRD2 61/4885HTR2A 33/4885DRD3 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.